Australia's most trusted
source of pharma news
Friday, 14 February 2025
Posted 4 February 2025 AM
Four PBS-listed drugs face generic competition for the first time in February, with first new brands being listed on drugs earning a collective $61.5 million in 2024.
AstraZeneca's heart drug Brilinta shifted to the F2 Formulary, with a 25 per cent drop in price, as two generic versions hit the PBS. In the calendar year 2024 Brilinta earned the pharma $28 million in pre-rebate R/PBS reimbursements, meaning a shave of $7 million a year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.